Modeling Mechanisms of Adjuvanted Influenza Vaccine Induced IgG Repertoire Diversity and Heterosubtypic Immunity
佐剂流感疫苗诱导 IgG 库多样性和异亚型免疫的建模机制
基本信息
- 批准号:10092077
- 负责人:
- 金额:$ 67.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-02-01 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAffinityAge-YearsAntibodiesAntibody AffinityAntibody DiversityB-Cell Antigen ReceptorB-LymphocytesBindingBiological AssayClone CellsComplementarity Determining RegionsCytoprotectionDNADNA SequenceDNA Sequence AlterationDataDevelopmentEpithelial CellsEvolutionFDA approvedFamilyFerretsFrequenciesGenerationsGenomicsGerm-Line MutationGoalsHeavy-Chain ImmunoglobulinsHemagglutininHumanHuman VolunteersImmuneImmune responseImmune systemImmunityImmunizationImmunizeImmunoglobulin GImmunoglobulin Somatic HypermutationImmunoglobulinsIn VitroIndividualInfection preventionInfluenzaInfluenza HemagglutininInfluenza vaccinationInternationalIntramuscularLightLymphocyteMF59MeasuresMediatingMethodsModelingMolecularMusMutationOilsPeptide Sequence DeterminationPhylogenetic AnalysisPhylogenyPlasmablastProcessProductionProteinsPublic HealthPublishingReactionSerumSialic AcidsSiteSomatic MutationSourceStructure of germinal center of lymph nodeSurfaceSurface Plasmon ResonanceTestingTreesVaccinatedVaccinationVaccine AdjuvantVaccine ProductionVaccinesViralVirusVirus DiseasesWorkage relatedanti-IgGanti-influenzabasecross reactivitycytokinefluhuman old age (65+)human subjectin vivoinfluenza infectioninfluenza virus straininfluenza virus vaccineinfluenzavirusinsightlymph nodesmathematical modelmolecular modelingnovel vaccinespandemic diseasepreventreconstructionrecruitseasonal influenzasuccesstranscriptome sequencingvaccination strategyvaccine responsevaccine-induced antibodies
项目摘要
Annual immunization against influenza infection is one of the largest coordinated international public health
efforts. Current flu vaccination strategies primarily elicit protection by the generating long lasting type-specific
neutralizing IgG anti-hemagglutinin (HA) antibodies that bind to molecularly similar influenza subtypes. This
phenomenon is termed antibody mediated heterosubtypic immunity (amHSI), and a major reason for the
success of seasonal influenza vaccination. MF59 is a squaline-oil adjuvant recently approved for seasonal
influenza vaccination in indivduals ≥65 years of age. Our preliminary data suggests that MF59 increases
amHSI in mice, ferrets and human subjects. Thus the primary goal of this Project is to elucidate and model the
mechanisms of by which MF59 adjuvanted seasonal influenza vaccine increase B cell mediated amHSI at the
immunoglobulin heavy chain DNA and protein repertoire level. Aim 1: To test the hypothesis that MF59
adjuvant increases the breadth, depth and molecular sequence diversity in the IgG repertoire after influenza
vaccination. Aim 2: To build and validate an age-dependent branching process model of heterosubtypic
immunity coverage induced by adjuvanted influenza vaccine. Aim 3: To model and identify the mechanisms
responsible for MF59 adjuvanted influenza vaccine induced anti-HA IgG repertoire evolution and amHSI
generation in human vaccine recipients. This proposal addresses a highly significant issue in public health, how
to optimize the protection of the influenza vaccine using vaccine adjuvants to increase the cross-strain reactivity
of the resulting mixture of IgG anti-HA antibodies. It also addresses a significant gap in scientific methods for
reconstructing Ig sequence lineages resulting from hyperaccellerated somatic mutation within germinal center
reactions. We will create age dependent branching process models that will provide mechanistic insight into
how the adjuvant and intradermal vaccination alter the molecular diversity of antibody-mediated HSI. These
models will be first developed using mice vaccinated with MF59 adjuvanted influenza vaccine in Aim 1, and
then extended to human subjects in Aim 2. If successful, this work will provide a general framework for
modeling the molecular processes involved in the generation of amHSI.
每年针对流感感染的免疫接种是最大规模的国际公共卫生协调行动之一
当前的流感疫苗接种策略主要通过产生持久的特定类型流感疫苗来引起保护。
中和 IgG 抗血凝素 (HA) 抗体,与分子相似的流感亚型结合。
这种现象被称为抗体介导的异亚型免疫(amHSI),这是造成这种现象的主要原因。
季节性流感疫苗接种取得成功 MF59 是一种角鲨烯油佐剂,最近被批准用于季节性流感疫苗接种。
我们的初步数据表明,≥65 岁的个体接种流感疫苗后,MF59 会增加。
因此,该项目的主要目标是阐明和模拟小鼠、雪貂和人类受试者中的 amHSI。
MF59 佐剂季节性流感疫苗增加 B 细胞介导的 amHSI 的机制
免疫球蛋白重链 DNA 和蛋白质库水平 目的 1:检验 MF59 的假设。
佐剂增加了流感后 IgG 库的广度、深度和分子序列多样性
目标 2:建立并验证异亚型的年龄依赖性分支过程模型。
佐剂流感疫苗诱导的免疫覆盖率 目标 3:建模并确定机制。
负责 MF59 佐剂流感疫苗诱导的抗 HA IgG 库进化和 amHSI
该提案解决了公共卫生领域的一个非常重要的问题,即如何进行疫苗接种。
使用疫苗佐剂提高交叉毒株反应性,优化流感疫苗的保护
由此产生的 IgG 抗 HA 抗体混合物也解决了科学方法中的重大空白。
重建生发中心内超加速体细胞突变产生的 Ig 序列谱系
我们将创建年龄相关的分支过程模型,以提供对反应的机制洞察。
佐剂和皮内疫苗接种如何改变抗体介导的 HSI 的分子多样性。
在目标 1 中,将首先使用带有 MF59 佐剂流感疫苗的小鼠疫苗开发模型,并且
然后扩展到目标 2 中的人类受试者。如果成功,这项工作将为
对 amHSI 生成所涉及的分子过程进行建模。
项目成果
期刊论文数量(23)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Highly Accurate and Robust Absolute Quantification of Target Proteins in Formalin-Fixed Paraffin-Embedded (FFPE) Tissues by LC-MS.
- DOI:10.1021/acs.analchem.2c03473
- 发表时间:2023-01-17
- 期刊:
- 影响因子:7.4
- 作者:Pu, Jie;Xue, Chao;Huo, Shihan;Shen, Qingqing;Qu, Yang;Yang, Xinxin;An, Bo;Angel, Thomas E.;Chen, Zhuo;Mehl, John T.;Tang, Huaping;Yang, Eric;Sikorski, Timothy W.;Qu, Jun
- 通讯作者:Qu, Jun
A Multiplex Microsphere IgG Assay for SARS-CoV-2 Using ACE2-Mediated Inhibition as a Surrogate for Neutralization.
- DOI:10.1128/jcm.02489-20
- 发表时间:2021-01-21
- 期刊:
- 影响因子:9.4
- 作者:Cameron A;Porterfield CA;Byron LD;Wang J;Pearson Z;Bohrhunter JL;Cardillo AB;Ryan-Muntz L;Sorensen RA;Caserta MT;Angeloni S;Hardy DJ;Zand MS;Pecora ND
- 通讯作者:Pecora ND
Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome-Level Effects of a Novel Combination Drug Therapy That Induces Cancer Cell Death via Metabolic Remodeling and Activation of the Extrinsic Apoptosis Pathway.
- DOI:10.1021/acs.jproteome.3c00463
- 发表时间:2023-10
- 期刊:
- 影响因子:4.4
- 作者:Sailee Rasam;Q. Lin;S. Shen;R. Straubinger;Jun Qu
- 通讯作者:Sailee Rasam;Q. Lin;S. Shen;R. Straubinger;Jun Qu
Continuous Readout versus Titer-Based Assays of Influenza Vaccine Trials: Sensitivity, Specificity, and False Discovery Rates.
流感疫苗试验的连续读数与基于滴度的测定:敏感性、特异性和错误发现率。
- DOI:10.1155/2019/9287120
- 发表时间:2019
- 期刊:
- 影响因子:0
- 作者:Li,Dongmei;Wang,Jiong;Garigen,Jessica;Treanor,JohnJ;Zand,MartinS
- 通讯作者:Zand,MartinS
Broad Cross-Reactive IgA and IgG against Human Coronaviruses in Milk Induced by COVID-19 Vaccination and Infection.
- DOI:10.3390/vaccines10060980
- 发表时间:2022-06-20
- 期刊:
- 影响因子:7.8
- 作者:Wang, Jiong;Young, Bridget E.;Li, Dongmei;Seppo, Antti;Zhou, Qian;Wiltse, Alexander;Nowak-Wegrzyn, Anna;Murphy, Katherine;Widrick, Kaili;Diaz, Nicole;Cruz-Vasquez, Joseline;M. Jarvinen, Kirsi;Zand, Martin S.
- 通讯作者:Zand, Martin S.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ollivier Hyrien其他文献
Ollivier Hyrien的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ollivier Hyrien', 18)}}的其他基金
Modeling Mechanisms of Adjuvanted Influenza Vaccine Induced IgG Repertoire Diversity and Heterosubtypic Immunity
佐剂流感疫苗诱导 IgG 库多样性和异亚型免疫的建模机制
- 批准号:
9332960 - 财政年份:2017
- 资助金额:
$ 67.58万 - 项目类别:
Statistical Inference on Chemotherapy Effects from Flow Cytometry Data
从流式细胞术数据对化疗效果的统计推断
- 批准号:
8132502 - 财政年份:2008
- 资助金额:
$ 67.58万 - 项目类别:
Statistical Inference on Chemotherapy Effects from Flow Cytometry Data
从流式细胞术数据对化疗效果的统计推断
- 批准号:
8320725 - 财政年份:2008
- 资助金额:
$ 67.58万 - 项目类别:
Statistical Inference on Chemotherapy Effects from Flow Cytometry Data
从流式细胞术数据对化疗效果的统计推断
- 批准号:
7691769 - 财政年份:2008
- 资助金额:
$ 67.58万 - 项目类别:
Modeling B Cell Vaccine Responses in Transplant Recipients
模拟移植受者的 B 细胞疫苗反应
- 批准号:
8790939 - 财政年份:2007
- 资助金额:
$ 67.58万 - 项目类别:
Modeling B Cell Vaccine Responses in Transplant Recipients
模拟移植受者的 B 细胞疫苗反应
- 批准号:
8423332 - 财政年份:2007
- 资助金额:
$ 67.58万 - 项目类别:
Modeling B Cell Vaccine Responses in Transplant Recipients
模拟移植受者的 B 细胞疫苗反应
- 批准号:
8606386 - 财政年份:2007
- 资助金额:
$ 67.58万 - 项目类别:
Modeling B Cell Vaccine Responses in Transplant Recipients
模拟移植受者的 B 细胞疫苗反应
- 批准号:
8292426 - 财政年份:2007
- 资助金额:
$ 67.58万 - 项目类别:
相似国自然基金
肿瘤微环境多层次调控的功能化纳米佐剂用于增强膀胱癌放疗疗效的机制研究
- 批准号:82303571
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向FPPS的双磷酸疫苗佐剂的开发
- 批准号:82341040
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
皮内接种抗原佐剂复合疫苗跨器官诱导呼吸道黏膜免疫反应
- 批准号:82341042
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
双重生物响应性自佐剂聚多肽载体构建高效mRNA癌症疫苗
- 批准号:52373299
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
新型免疫调节复合佐剂的机制研究及在疫苗开发中的应用
- 批准号:82341039
- 批准年份:2023
- 资助金额:95 万元
- 项目类别:专项基金项目
相似海外基金
Multidomain Peptide Hydrogels as a Therapeutic Delivery Platform for Cancer Treatment
多域肽水凝胶作为癌症治疗的治疗传递平台
- 批准号:
10743144 - 财政年份:2023
- 资助金额:
$ 67.58万 - 项目类别:
2023 International Society for Vaccines (ISV) Annual Congress, October 22-25, Lausanne, Switzerland
2023 年国际疫苗协会 (ISV) 年会,10 月 22 日至 25 日,瑞士洛桑
- 批准号:
10754840 - 财政年份:2023
- 资助金额:
$ 67.58万 - 项目类别:
Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer
双特异性适体的分子工程和系统评估,以开发有效的非小细胞肺癌免疫调节疗法
- 批准号:
10751309 - 财政年份:2023
- 资助金额:
$ 67.58万 - 项目类别:
"Extended dosing" immunization to enhance humoral immunity to next-generation vaccines
“延长剂量”免疫增强对下一代疫苗的体液免疫
- 批准号:
10638732 - 财政年份:2023
- 资助金额:
$ 67.58万 - 项目类别: